TXG Stock: Price, Earnings History and SEC Filings
10x Genomics, Inc. (TXG) last traded at $70.11, down 14.03% on the latest session and down 22.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.14 against an analyst estimate of $-0.23, a beat of 39.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TXG earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.14 | $-0.23 | +39.13% |
| Mar 2026 | May 7, 2026 | $-0.10 | $-0.29 | +65.52% |
| Dec 2025 | Feb 12, 2026 | $-0.13 | $-0.19 | +31.58% |
| Sep 2025 | Nov 6, 2025 | $-0.22 | $-0.27 | +18.52% |
TXG beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How TXG reacts to earnings
Across its last 8 earnings releases, TXG moved 6.0% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | +14.10% |
| 2026-05-07 | After close | -3.66% |
| 2026-02-12 | After close | +3.48% |
| 2026-01-12 | Before open | -3.23% |
| 2025-11-06 | After close | +17.31% |
| 2025-08-07 | After close | -3.98% |
| 2025-05-08 | After close | +1.62% |
| 2025-02-12 | After close | -0.50% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
TXG financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $643M | -$44M | $130M | -6.8% | $-0.35 |
| 2024 | $611M | -$183M | -$6M | -29.9% | $-1.52 |
| 2023 | $619M | -$255M | -$64M | -41.2% | $-2.18 |
| 2022 | $516M | -$166M | -$165M | -32.1% | $-1.46 |
| 2021 | $490M | -$58M | -$123M | -11.9% | $-0.53 |
| 2020 | $299M | -$543M | -$255M | -181.6% | $-5.37 |
| 2019 | $246M | -$31M | -$8M | -12.7% | $-0.80 |
| 2018 | $146M | -$112M | -$83M | -76.9% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for TXG
- 10-Q · Aug 7, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 8, 2026Shareholder vote
- 10-Q · May 8, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 24, 2026
- 10-K · Feb 13, 2026
- 8-K · Feb 12, 2026Results of operations, Financial statements and exhibits
- 8-K · Jan 12, 2026Results of operations
- 8-K · Nov 14, 2025Officer or director change
Insider filing activity
TXG insiders filed 13 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TXG news
- 3 Promising Genomics Stocks to Add to Your Portfolio NowOct 30, 2026 · finance.yahoo.com
- Will TXG Stock Ever Get Back To Its Old High?Oct 30, 2026 · trefis.com
- Single-Cell eQTL Clinical Workflows Market Forecast to Reach $4.51 Billion by 2030 | Capitalize on 19.9% CAGR with Illumina, QIAGEN, 10x Genomics, Singleron and MoreOct 29, 2026 · finance.yahoo.com
- Slide-DNA-Sequencing for Copy Number Mapping Global Market Report 2026 | Capitalize on AI and Spatial Genomics with Illumina, 10x Genomics and BGI GenomicsOct 29, 2026 · finance.yahoo.com
- Long-Read Full-Length cDNA Sequencing Global Market Report 2026 | Capitalize on 18.9% CAGR and Single-Cell Demand With PacBio, Oxford Nanopore, 10x Genomics and QIAGENOct 29, 2026 · finance.yahoo.com
- Butterfly Network, Inc. (BFLY) Reports Q3 Loss, Beats Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Twist Bioscience Soars 12%, 10x Genomics Up 12% as Genomics Stocks ReboundOct 28, 2026 · tikr.com
- Absci Soars 12%, Schrödinger Up 11%, Recursion Up 9% as AI Drug Discovery Stocks RallyOct 28, 2026 · tikr.com
About 10x Genomics, Inc.
10x Genomics, Inc. (TXG) is a US-listed public company on Nasdaq. The SEC classifies its business as Laboratory Analytical Instruments. It is incorporated in DE. Its fiscal year ends in December.